Plecanatide vs Dulaglutide
Head-to-head comparison of Plecanatide (Plecanatide) and Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Dulaglutide |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Plecanatide | Recombinant GLP-1 receptor agonist Fc fusion protein |
| Molecular Weight | Approx. 1620 Da | ~63,000 Da |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | About 5 days |
| Amino Acids | 16 | N/A |
| Typical Dose | 3 mg once daily | 0.75-4.5 mg weekly |
| Route | Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 700 |
| Research Status | Clinical | Approved |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.